Brief: FDA Accepts Biologics License Application For Mucopolysaccharidosis II Treatment
14/05/2025 13:04
May 14 (Reuters) - Regenxbio Inc RGNX.O: FDA ACCEPTS BIOLOGICS LICENSE APPLICATION FOR MUCOPOLYSACCHARIDOSIS II TREATMENT REGENXBIO INC - FDA GRANTS PRIORITY REVIEW WITH PDUFA DATE NOVEMBER 9, 2025 Source text: ID:nPn8LTm8Ta Further company coverage: RGNX.O ((Reuters.Briefs@thomsonreuters.com;))